Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NASDAQ:ENGN

enGene Q2 2025 Earnings Report

enGene logo
$1.80 +0.03 (+1.69%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$1.80 +0.00 (+0.11%)
As of 09/11/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

enGene EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

enGene Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

enGene Announcement Details

Quarter
Q2 2025
Date
6/10/2025
Time
Before Market Opens
Conference Call Date
Thursday, June 12, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

enGene's Q2 2025 Press ReleasePress Release
(8-K)
enGene's Q2 2025 Quarterly reportQuarterly report
(10-Q)

enGene Earnings Headlines

Citizens Jmp Reaffirms "Market Perform" Rating for enGene (NASDAQ:ENGN)
September 11 at 2:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31015984
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market
September 10 at 4:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4945223-engene-therapeutics-slashing-cash-burn-to-bring-their-asset-to-the-market
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
September 13 at 1:00 AM  |  Profits Run (Ad)
enGene (NASDAQ:ENGN) Earns Buy Rating from HC Wainwright
September 10 at 1:30 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31013743
Lucas Oil Motor Oil Extender supports engine protection amid rising costs
September 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/energy/articles/lucas-oil-motor-oil-extender-165700783.html
Toyota Tundra replacement engine teardown finds spun main bearing
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/autos/general/toyota-tundra-replacement-engine-teardown-finds-spun-main-bearing/ar-AA2bSeoW
See More enGene Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email.

About enGene

enGene (NASDAQ:ENGN) is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

View enGene Profile
Earnings Tools